The Eucalyptus globulus essential oil (EGEO) is widely recognized for its pharmacological relevance; however, comprehensive evaluation of its phytochemical composition and bioactivities remains limited. In this study, EGEO was extracted from fresh leaves via hydro-distillation and characterized using GC-MS, LCMS, FTIR, and UV-Visible spectroscopy. Qualitative screening confirmed the presence of key secondary metabolites, including triterpenoids, flavonoids, phenols, steroids. Quantitative analysis revealed high levels of total phenolics (65.12 ± 0.01 mg GAE/g) and flavonoids (57.75 ± 0.01 mg QE/g). The oil exhibited concentration-dependent antioxidant activity in the DPPH assay with an IC₅₀ value of 604.01 µl/mL, indicating potent radical-scavenging ability. Anti-inflammatory assessment through protein denaturation and human red blood cell (HRBC) membrane stabilization assays demonstrated moderate inhibitory and cytoprotective effects comparable to standard drugs. EGEO also showed strong antibacterial efficacy against Tannerella forsythia, Prevotella intermedia and Aggregatibacter with inhibition zones of 19-25 mm while showed notable antibiofilm activity against T. forsythia. Cytotoxic evaluation indicated selective action, showing minimal toxicity toward normal L929 fibroblasts and moderate inhibition of B16F10 melanoma cells. Overall, these findings suggest that Eucalyptus globulus essential oil is a rich source of bioactive phytoconstituents with potential therapeutic applications as a natural antioxidant, anti-inflammatory, antibacterial, antibiofilm, and anticancer agent.
ADMET analysis predicted favorable pharmacokinetic and safety profiles. Collectively, these findings identified compound 7e as a promising dual VEGFR-2/CDK6 inhibitor with potent and selective anticancer activity, warranting further preclinical investigation.
Asian Pacific Journal of Cancer Prevention · مجلد 27 (8) · 2853-2860
BACKGROUND: Retinoblastoma (Rb) represents the most frequent primary intraocular cancer in the pediatric population; yet comprehensive national data are limited in Saudi Arabia due to incomplete cancer registry coverage and underreporting. The present study systematically investigates the incidence, distribution, and trends of retinoblastoma across Saudi Arabia over two decades, utilizing robust data from the Saudi National Cancer Registry (SCR), a nationwide surveillance system overseen by the Ministry of Health. METHODS: This retrospective population-based analysis included all children diagnosed with Rb in Saudi Arabia between January 1, 2000, and December 31, 2019. The study examined incidence rates and temporal patterns by age, regional location, and tumor histology. RESULTS: Out of 542 documented cases (258 females, 284 males), the age-standardized incidence rate (ASIR) for children aged 0-4 years demonstrated an initial increase, peaking at 1.26 per 100,000 in 2003, followed by a gradual decline to 0.93 per 100,000 by 2019. Higher incidence rates were detected in major urban centers, especially Riyadh and Makkah, likely reflecting demographic density, enhanced diagnostic practices, and more accessible specialized care. Most tumors were either undifferentiated (Grade IV) or not otherwise specified (NOS, 63%), while diffuse retinoblastoma was rare (2%). Diagnosis was predominantly confirmed by histopathological evaluation (88.3%). CONCLUSION: This study offers the most comprehensive picture to date of retinoblastoma incidence and patterns in Saudi Arabia. The observed rising incidence, together with regional disparities, emphasizes the need for more refined cancer surveillance, equitable resource allocation, and accelerated early detection strategies, particularly in underserved areas. These findings provide essential baseline metrics to inform national cancer control policies and optimize equitable resource distribution.
retinoblastomapediatric cancer incidenceSaudi Arabiaage-standardized incidence rate
BACKGROUND: Given the rising incidence of endometrial cancer in Saudi Arabia, the integration of high-cost therapeutics, such as dostarlimab (DSR), for primary advanced or recurrent (pA/rEC) disease necessitates rigorous economic appraisal. Therefore, this study aimed to evaluate the cost-utility of first-line dostarlimab plus carboplatin-paclitaxel (DSR + CP) versus placebo plus carboplatin-paclitaxel (PBO + CP) from the perspective of the Saudi healthcare payer. METHODS: A partitioned survival model was constructed to simulate patient prognosis across three health states: progression-free disease, progressive disease, and death. The model parameters were derived from the clinical efficacy data of the RUBY trial and the local cost inputs. The primary outcome was the incremental cost-effectiveness ratio (ICER), the robustness of which was evaluated via comprehensive deterministic and probabilistic sensitivity analyses to characterize parameter uncertainty. RESULTS: For the overall pA/rEC population, the DSR + CP regimen yielded an incremental 1.55 quality-adjusted life-years (QALYs) at an additional cost of $144,716, resulting in an ICER of $93,244 per QALY. Cost-effectiveness was more favorable in the mismatch repair deficient (dMMR) subgroup (ICER: $82,754/QALY) than in the mismatch repair proficient (pMMR) cohort (ICER: $132,571/QALY). The ICER is the most sensitive to the acquisition cost of the DSR. At a willingness-to-pay threshold of $90,000/QALY, the probability of DSR + CP being cost-effective was 83.9% for the dMMR subgroup. CONCLUSION: This economic evaluation indicates that DSR + CP constitutes a cost-effective intervention for pA/rEC within the dMMR subpopulation. These findings provide strong evidence for a tailored reimbursement policy that effectively utilizes resources by connecting clinical benefits with economic value in the management of pA/rEC.
Globally, environmental pollution caused by resilient protein like collagen is escalating due to inefficient disposal practices. Accumulation of collagen waste poses ecological threat, necessitating management strategies. Current study discloses collagenolytic bacterium, Bacillus siamensis strain Z1, isolated from marine water (Goa) demonstrating collagen breakdown and inducing collagenase biosynthesis. Production kinetics revealed optimal collagenase production (4.55 U/mL) on 2nd day with a protein content of 0.69 mg/mL. Influence of physiochemical parameters, including inoculum size, metal ions, carbon and nitrogen sources, pH and temperature on collagenase yield was optimized achieving 17.93 folds enhancement by central composite design. Silver (AgNP) and Zinc oxide (ZnONP) nanoparticles were biosynthesized using collagen hydrolysate derived from marine collagen through collagenase action and characterized using UV-Visible spectroscopy, Fourier Transform Infrared Spectroscopy, X-ray Diffraction, Scanning Electron Microscopy with Energy Dispersive X-ray, Thermogravimetric Analysis and Atomic Force Microscopy elucidated thermostability, structure and surface characteristics. Antibacterial effect of nanoparticles was observed against B. cereus and E. coli. AgNP and ZnONP demonstrated antioxidant properties assessed by ABTS and DPPH assays. AgNP and ZnONP exhibited cytotoxicity on MCF-7 breast cancer cell lines, with IC50 values 8.87 µg/mL and 25.21 µg/mL respectively. The study highlights biotechnological potential of collagenase in generating bioactive products for therapeutical and biomedical advancements.
Objectives This study aimed to assess the effects of incorporating Kinesio-taping (KT) into a chest physical therapy program on alleviating pain and enhancing pulmonary function, respiratory muscle strength, and quality of life following mastectomy. Design This was a prospective, randomized controlled trial. Setting Physiotherapy outpatient clinic. Participants Sixty participants aged 30–50 years who had undergone modified radical mastectomy were randomly allocated to either the Kinesio-taping or traditional physical therapy exercise group. Intervention The Kinesio-taping group received both Kinesio-taping and traditional chest physiotherapy. The control group received only the traditional chest physiotherapy program. The interventions were administered over a 4-week period. Outcome measures The primary outcome measure was pain, which was evaluated using a visual analogue scale (VAS). Secondary outcomes included pulmonary function, specifically forced vital capacity (FVC) and forced expiratory volume in one second (FEV1), assessed via spirometry; respiratory muscle strength, determined by measuring maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) using a portable pressure device; and quality of life, assessed using the Short Form-36 (SF-36) questionnaire. All outcomes were measured at baseline and 4 weeks after the intervention. Results The evaluated parameters exhibited significant alterations between the pre- and post-intervention after a duration of 4 weeks in both groups. The results indicated a significant changes ( p < 0.001) in post-intervention measures compared to pre-intervention measures in both groups. No significant differences were observed between the groups before the intervention. The KT group demonstrated superior postintervention outcomes. Specifically, the KT group showed a significant reduction in VAS scores post-intervention than the control group (3.97 ± 1.65 vs. 6.50 ± 1.57, p < 0.001). Post-intervention, the KT group exhibited significantly higher values ( p < 0.001) of FVC, FEV1, and FEV1/FVC (3.52 ± 0.64 L, 2.95 ± 0.56 L, and 85.09 ± 12.07%) compared to the control group (2.38 ± 0.56 L, 1.74 ± 0.54 L, and 72.39 ± 10.82%), respectively. Additionally, post-intervention MIP and MEP values were significantly higher ( p < 0.001) in the KT group. Conclusion Integrating Kinesio-taping into a standard chest physiotherapy program significantly reduced pain and enhanced pulmonary function, respiratory muscle strength, and quality of life in post-mastectomy patients compared to the application of traditional chest physiotherapy alone. Clinical trial registration ClinicalTrials.gov , identifier NCT06701591.
= 1.79 ± 0.05 µM), supporting its targeted anti-angiogenic mechanism. Flow cytometry analysis showed that 7e induced G0/G1 cell cycle arrest and markedly increased apoptotic cell populations. This was further confirmed by upregulation of Bax, Caspase-3, and Caspase-8, alongside downregulation of Bcl-2, indicating activation of both intrinsic and extrinsic apoptotic pathways. Interestingly, 7e inhibited cancer cell migration, suggesting a potential anti-angiogenetic effect. Density functional theory (DFT) calculations revealed that 7e possesses a conjugated electronic system with a suitable frontier orbital distribution, moderate HOMO-LUMO gap, and a favorable electrostatic potential for receptor interaction. Molecular docking and dynamics simulations demonstrated stable binding of 7e within the VEGFR-2 active site, supported by consistent RMSD, hydrogen bonding, and compact structural behavior. MM-GBSA calculations confirmed favorable binding free energy, while per-residue decomposition and protein-ligand interaction fingerprint analysis identified key stabilizing interactions. Essential dynamics and free energy landscape mapping further confirmed a stable and energetically favorable conformational state. ADMET and toxicity predictions indicated acceptable pharmacokinetic properties, low mutagenic risk, and an overall favorable safety profile. Collectively, these findings identify compound 7e as a promising VEGFR-2-targeted anticancer lead with strong enzymatic inhibition, potent cytotoxicity, and a well-supported mechanistic profile integrating experimental and computational evidence.
Background Breast cancer is the most prevalent female malignancy in Saudi Arabia and globally, with early detection being the cornerstone of improved survival. This study assesses breast cancer screening awareness, knowledge of risk factors and signs, and screening practices among non-medical female university students in Riyadh, Saudi Arabia. Methods A cross-sectional study (July-September 2025) enrolled 679 non-medical female students aged 18 years and above from four Riyadh universities using multistage sampling. Data were collected using a structured, bilingual 58-item questionnaire adapted from previous studies, culturally modified, pilot-tested, and reviewed by experts. Knowledge and practice domains were classified as sufficient when scores exceeded 60% and insufficient when scores were ≤60%. Knowledge scores were analyzed using Mann-Whitney U and Kruskal-Wallis tests with Bonferroni correction; chi-square tests and multivariate logistic regression identified significant predictors. Results Despite 85% (n = 578) demonstrating sufficient attitudes toward screening, only 44% (n = 299) had adequate general awareness, 19% (n = 132) had sufficient knowledge of risk factors and signs, and 23% (n = 158) achieved sufficient screening practice. The median knowledge score was 19/43 (IQR: 16-22). Family history (65.5%, n = 445) and increasing age (56.7%, n = 385) were the most recognized risk factors, while early puberty (16.2%, n = 110) and nulliparity (23.6%, n = 160) were the least. While 90.9% (n = 617) identified a breast mass as a sign, only 5.9% (n = 40) correctly recognized that a painful mass is not a typical early presentation. Breast self-examination and clinical breast examination uptake were low at 40.4% (n = 274) and 23.4% (n = 159), respectively. However, these screening practice findings should be interpreted considering the young age distribution of participants, with many being below the recommended age for routine mammography screening. AlMaarefa University affiliation was the strongest predictor of knowledge (OR = 2.718; 95% CI: 1.398-5.282; p = 0.003) and screening practice (OR = 5.488; 95% CI: 2.863-10.519; p < 0.001), with family history also predicting sufficient screening practice (OR = 2.384; 95% CI: 1.488-3.819; p < 0.001). Conclusion A striking knowledge-attitude-practice gap exists in this population. Universities are underutilized platforms for breast cancer health education, and structured, culturally sensitive interventions are urgently needed to convert attitudinal willingness into consistent screening practice.
breast cancer screeningknowledge-practice gapfemale university studentsbreast cancer risk factors
Background/Objectives: Repurposing existing drugs may represent a promising strategy for effective cancer therapy. This study was the first to investigate the augmented antitumor therapeutic effect achieved by co-incorporating the NSAID Niflumic acid (NIF) with ceramides into PEGylated cerosomes (NIF-loaded PEG-CERs) in a novel platform that targets specifically the MAPK-ERK signaling pathway and miR-21-5p modulation. Methods: The prepared formulae were statistically optimized utilizing a full factorial design and the optimal formula (C5) was further incorporated into a topical gel and evaluated for ex vivo rat skin permeation, and tested in vivo in a subcutaneous solid Ehrlich carcinoma (SEC) mice model. Results: The optimal formula (C5) showed tubular elongated morphology with higher EE% (96.71 ± 0.0), lower vesicular size (VS) and PDI values, 292.95 ± 0.78 nm and 0.47 ± 0.0 respectively. A high ZP value (−37.5 ± 0.57 mV) was in accordance with stability results showing good stability of the optimal formula (C5). Permeability studies exhibited 2.02-fold higher skin permeation compared to pure NIF gel. A significant decrease in tumor volume and marked improvement in survival rate in SEC mice were confirmed by downregulation of EGFR, ERK1, ERK2, and miR-21-5p expression. Furthermore, an increase in total antioxidant capacity and caspase-3 levels was observed, accompanied by significant suppression in cyclin D1, MMP-2, COX-2, and MDA levels. Finally, histopathological analysis revealed the superior antitumor effect of C5 gel together with immunohistochemical assay showing the lowest BCL-2-positive staining, indicating the restoration of physiological apoptotic balance. Conclusions: Based on the previous findings, NIF-loaded PEG-CERs offer augmented therapeutic potential for efficient topical skin cancer management in an SEC mice model.
Aims This study aimed to design, synthesize, and evaluate novel benzanilide derivatives as potential anticancer agents targeting VEGFR-2-mediated tumor angiogenesis.Materials and methods Eight benzanilide derivatives (7a-e, 9a-b, and 11) were synthesized and structurally confirmed using spectroscopic methods. The compounds were evaluated via molecular docking, in silico ADMET profiling, in vitro cytotoxicity against MCF-7, MDA-MB-231, HepG-2, and HCT-116 cancer cell lines, and selectivity assessment using WI-38 and WISH normal cell lines. VEGFR-2 enzyme inhibition was also determined for the most active compound.Results Compound 11 exhibited the highest cytotoxic activity with IC50 values of 6.08, 5.76, 7.94, and 4.64 µM against MCF-7, MDA-MB-231, HepG-2, and HCT-116, respectively, comparable to sorafenib. It showed potent VEGFR-2 inhibition (IC50 = 0.414 µM) superior to sorafenib (0.809 µM). Mechanistic studies indicated activation of apoptosis via upregulation of Bax, Caspase-3, and Caspase-8 and downregulation of Bcl-2. ADMET results revealed favorable pharmacokinetic properties and acceptable safety profiles.Conclusions Compound 11 represents a promising VEGFR-2 inhibitor with potent anticancer activity and favorable drug-like properties, warranting further optimization and development.
Archiv der Pharmazie · مجلد 359 (9) · e70328-e70328
ABSTRACT A new series of chromene derivatives ( 12–19 ) was rationally designed as potential inhibitors of vascular endothelial growth factor receptor‐2 (VEGFR‐2) by integrating essential pharmacophoric and structural features. The target compounds were synthesized and structurally confirmed using spectroscopic techniques. Their in vitro antiproliferative activities were evaluated against a panel of human cancer cell lines (MCF‐7, MDA‐MB‐231, HepG‐2, and HCT‐116) alongside normal human cells (WI‐38 and WISH), in addition to a VEGFR‐2 enzyme inhibition assay. Among the synthesized derivatives, compound 17 emerged as the most potent candidate, displaying low micromolar IC 50 values across all tested cancer cell lines and superior VEGFR‐2 inhibitory activity (IC 50 = 0.518 µM) compared with the reference drug sorafenib (IC 50 = 0.809 µM). Mechanistic investigations revealed that compound 17 induced pronounced cell cycle arrest and triggered apoptosis, as demonstrated by Annexin V–FITC/PI flow cytometric analysis. Computationally, Density Functional Theory (DFT) calculations demonstrated favorable electronic properties for compound 17, supporting effective ligand–receptor interactions. Molecular docking and 100‐ns molecular dynamics (MD) simulations, complemented by MM‐GBSA binding free energy calculations, Protein–Ligand Interaction Fingerprinting (Pro‐LIF), Principal Component Analysis (PCA‐T), and Free Energy Landscape (FEL) analyses, confirmed the stability and favorable binding energetics of compound 17 within the VEGFR‐2 active site. Furthermore, in silico ADME–Tox profiling predicted acceptable pharmacokinetic behavior and a favorable safety profile. Collectively, these experimental and computational findings identify compound 17 as a promising and mechanistically well‐characterized VEGFR‐2 inhibitor, warranting further in vivo investigation.
Sultan Qaboos University medical journal · مجلد 26 (1) · 455-465
Objectives: Breast cancer (BC) is the most common malignancy among women worldwide and represents a significant burden for Yemeni women. Early detection through breast self-examination (BSE) and knowledge of risk factors and symptoms are crucial. This study aimed to assess awareness, knowledge and practice regarding BC risk factors, symptoms and BSE among female healthcare workers (HCWs) in Al-Mukalla, Yemen. Methods: This cross-sectional study was conducted from September to October 2022 at three public hospitals in Al-Mukalla, Yemen. A census sampling approach was used to recruit HCWs. Data were collected using a validated self-administered questionnaire covering breast awareness practices, risk factor awareness, symptom recognition and BSE frequency. Descriptive statistics and logistic regression were used to identify BSE predictors. Results: A total of 151 HCWs were included in this study (response rate = 83.0%). The mean participant age was 30.4 ± 6.1 years; 49.7% were aged 20–29 years. Most participants were unmarried (66.2%), university-educated (57.0%) and doctors (47.0%). Knowledge of hallmark symptoms such as breast masses (90.0%) was high; however, 51.0% misidentified the specific laterality (right upper outer quadrant) of the most common cancer site, rather than the quadrant itself. Regular (monthly) BSE was reported by 71.5% of participants. Multivariable analysis showed that nurses were less likely than doctors to perform BSE (adjusted odds ratio [aOR] = 0.32, 95% confidence interval [CI]: 0.14–0.73; P = 0.007). Diploma holders practised BSE less than university graduates (aOR = 0.38, 95% CI: 0.19–0.78; P = 0.008), while higher BC knowledge independently predicted greater BSE practice (aOR = 2.15, 95% CI: 1.10–4.20; P = 0.025). Conclusion: Despite good symptom awareness, significant knowledge gaps remain regarding risk factors and breast anatomy among female HCWs in Al-Mukalla, Yemen. BSE practice is still suboptimal, influenced by professional role, education level and BC knowledge. Targeted interventions focusing on breast awareness and structured education are urgently required.
breast cancerbreast self-examinationbreast cancer screeningbreast cancer knowledge
Background Irinotecan is a potent chemotherapeutic agent used as a neoadjuvant in colorectal cancer liver metastasis and significantly enhances five-year survival rates. Recently, irinotecan-associated hepatotoxicity was a significant concern. Given the limited study in this area, we aimed to identify risk factors associated with irinotecan-induced hepatotoxicity. Methods This is a retrospective cohort study at King Saud University Medical City in Riyadh. The study encompassed all adult cancer patients who received irinotecan treatment between Jun 2017 and December 2023. The clinical records of patients were reviewed to assess factors associated with hepatotoxicity. Time-to-event analyses were performed using time-varying exposure. Results The study includes 229 adult cancer patients who received irinotecan-based treatment. Median age was 58 years, and colorectal cancer was the most diagnosed type of cancer (68.6%). Over a median follow-up of 103 days, the incidence of hepatotoxicity was 19.2% (n=44). In the adjusted analysis, higher baseline AST was associated with an increased hazard of hepatotoxicity (HR = 1.01; 95% CI: 1.01–1.02; p = 0.001). Cumulative irinotecan dose showed an inverse association with hepatotoxicity, with lower hazards observed in the medium cumulative dose group (HR = 0.36, 95% CI: 0.14–0.91, p = 0.031) and high cumulative dose group (HR = 0.06, 95% CI: 0.01–0.48, p = 0.008) compared with the low cumulative dose group. Conclusion In summary, an inverse association was observed between cumulative irinotecan dose and hepatotoxicity. A higher baseline AST was also associated with hepatotoxicity, warranting careful assessment of pretreatment liver enzymes and closer monitoring during the early treatment period. Further studies are needed to validate these findings and investigate additional predictors of irinotecan-related hepatotoxicity.
Annals of Medicine and Surgery · مجلد 88 (7) · 4020-4033
Background: Population screening and therapeutic advances have changed colorectal cancer (CRC) incidence and survival over recent decades, yet important differences exist by anatomic subsite, histology, and population subgroup. This study describes long-term trends in incidence and survival for colon and rectal tumors. Methods: We analyzed 501 094 primary colon and rectal tumor records from the Surveillance, Epidemiology, and End Results (SEER) Incidence database (1975–2022). Age-adjusted rates used the 2000 U.S. standard population. Outcomes were overall survival (OS) and CRC-specific mortality. OS was estimated using Kaplan–Meier methods and compared between groups by log-rank tests. CRC-specific mortality was evaluated using cause-specific Cox regression based on SEER cause-of-death recodes, adjusting for age, sex, race, histology, primary site, and surgery status. Results: Age-adjusted incidence was 48.3 per 100 000. Median OS improved across eras [Era 1 (1975–1994) 3.83 years, Era 2 (1995–2009) 5.58 years, and Era 3 (2010–2022) 6.92 years, all Eras had P value < 0.001). Left- versus right-sided colon cancers and rectal versus colon primaries showed fixed survival differences across eras. Regarding histology, the signet-ring tumors had markedly worse survival, while neuroendocrine/carcinoid tumors showed better long-term survival. In the adjusted Cox model, several colonic subsites showed a higher hazard of CRC-specific death compared to the appendix. Signet-ring cell histology conferred the greatest mortality risk (HR = 2.206, 95% CI 2.113–2.304; P < 0.001). Conclusions: Over a 47-year period, survival in CRC has significantly improved, but outcomes remain influenced by anatomic subsite and histology. These findings confirm that tumor subsite and histology remain important determinants of long-term prognosis in CRC and highlight the need for risk-adapted management strategies, continued population-based surveillance, and ongoing efforts to address disparities in outcomes.
Niclosamide, an FDA-approved anti-helminthic drug, has attracted attention for its potential to target multiple cancer-related pathways. This study evaluated the chemopreventive effect of niclosamide in a DMBA/TPA-induced mouse model of skin carcinogenesis and explored its mechanisms using integrated biological and network-based approaches. Mice were treated with niclosamide at 15, 30, and 45 mg/kg and compared with healthy, disease, and standard therapy controls. Tissue and serum analyses were conducted to measure markers of inflammation (TNF-α, IL-6, IL-1β), oxidative stress (MDA, SOD, GSH), apoptosis (caspase-3, Bax/Bcl-2), and angiogenesis (VEGF). Niclosamide reduced tumor volume in a dose-dependent manner, suppressed inflammatory cytokines, restored antioxidant levels, activated apoptotic signaling, and downregulated VEGF expression. A protein-protein interaction network was constructed using eleven experimentally relevant genes to identify key regulatory modules. Network topology and enrichment analysis revealed two functional clusters associated with inflammation, apoptosis, and redox homeostasis. Hub genes such as TNF, IL6, CASP3, and GPX1 highlighted potential interactions among pathways affected by niclosamide. Thus, these findings suggest that niclosamide may exert anticancer effects by modulating interconnected pathways related to inflammation, oxidative stress, apoptosis, and angiogenesis, supporting its potential for further investigation as a repurposed therapeutic candidate for skin cancer.